Physician profile
Mark W Jackson
NPI 1699745273
$1,695.17
in general payments reported to CMS, 2019-2025
13 companies · $71.75 in 2025
The $71.75 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $178 · 2021: $575 · 2022: $495 · 2023: $133 · 2024: $67.46 · 2025: $71.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.99 | 2019-2023 | |
| Boston Scientific Corporation | $165.19 | 2019-2025 | Axios, Apollo Esg Nxt System |
| Supernus Pharmaceuticals, INC. | $145.28 | 2021 | |
| Janssen Biotech, INC. | $131.52 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.15 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.64 | 2020-2023 | Entyvio |
| Daiichi Sankyo INC. | $50.39 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $42.19 | 2019-2025 | Adstiladrin |
| Celgene Corporation | $34.93 | 2023 | Zeposia |
| Pfizer INC. | $17.97 | 2020 | |
| Ucb, INC. | $16.79 | 2019 | |
| Romark Laboratories, Lc | $16.56 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.